 CAMBRIDGE, Mass., May 11, 2021 GLOBE NEWSWIRE -- Voyager Therapeutics, Inc. NASDAQ: VYGR, a clinical-stage gene therapy company focused on developing life-changing treatments for serious neurological diseases, today will present new preclinical data demonstrating high transduction efficiency of the companys novel adeno-associated virus AAV capsids in the central nervous system CNS after intravenous dosing in non-human primates. Data will be presented at the 24th Annual Meeting of the American Society of Gene and Cell Therapy ASGCT taking place virtually May 11-14, 2021. 